Thomas Barnes from Intellia Therapeutics gave a talk to Corn Lab

The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

January 23, 2023

Welcome to Alessandra!

Alessandra Albertelli received her Master’s degree in Medical Biotechnology and Molecular Medicine from the University of Milan in 2017. In her Master’s...

December 9, 2022

Welcome back Martina!

Martina received her MSc in Biology from ETH Zurich in September 2022. She worked in the Corn lab, focusing on the role of the ubiquitin-proteasome system in...

December 4, 2022

BASE EDITING AS A POTENTIAL CURE FOR FANCONI ANEMIA – PUBLISHED IN NATURE COMMUNICATIONS

Cas-mediated genome editing technology holds great promise as a curative treatment for a number of genetic diseases. Conventional CRISPR-Cas genome editing...

News Archive

Tweets